1,5,6-trimethyl-2(1H)-pyrazinone | 137232-63-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1,5,6-trimethyl-2(1H)-pyrazinone
• 英文别名: 1,5,6-trimethylpyrazin-2-one
• CAS: 137232-63-4
• 化学式: C₇H₁₀N₂O
• 分子量: 138.169
• InChiKey: FUCUUWDBHGJYML-UHFFFAOYSA-N

物化性质

• 沸点：
  207.2±23.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)
• 保留指数：
  1423

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  草酸醛 、 聚甘氨酸 生成 1,5-dimethylpyrazin-2-one 、 1,6-二甲基-2(1H)-吡嗪酮 、 1,5,6-trimethyl-2(1H)-pyrazinone
  参考文献：
  名称：

  Elucidation of the Mechanism of Pyrazinone Formation in Glycine Model Systems Using Labeled Sugars and Amino Acids

  摘要：

  Model studies using D-[C-13]glucoses and a series of C-2, C-3, and C-4 dicarbonyl compounds with labeled [N-15/C-13]glycines have indicated that methyl-substituted pyrazines and pyrazinones formed in these model systems have a common intermediate. The labeling studies have also helped to identify a new chemical transformation of alpha-dicarbonyls, affected by the amino acid, that lead to the addition of the C-2 atom of the amino acid to the alpha-dicarbonyl compounds, instead of the amino group as in the case of the Strecker-type interaction between the two reactants. Thus, glyoxal and pyruvaldehyde can be transformed into pyruvaldehyde and 2,3-butanedione, respectively, by the amino acid. Two pathways of formation of pyrazinones were distinguished on the basis of the labeling experiments, one involving the reaction of 3 mol of glycine and the other the interaction of the dipeptide glycylglycine with an alpha-dicarbonyl compound.

  DOI：

  10.1021/jf960067z

文献信息

• FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
  申请人：Matsunaga Nobuyuki

  公开号：US20130131050A1

  公开（公告）日：2013-05-23

  The present invention provides a compound useful for the prophylaxis or treatment of eicosanoid-associated diseases such as atherosclerosis, atherothrombosis, diabetes, obesity, asthma, fever, pain, cancer, rheumatism, osteoarthritis, atopic dermatitis and the like, and having superior pharmacological action, physicochemical properties and the like. The present invention relates to a compound represented by the following formula: wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种化合物，用于预防或治疗与前列腺素相关的疾病，如动脉粥样硬化、动脉血栓形成、糖尿病、肥胖、哮喘、发热、疼痛、癌症、风湿病、骨关节炎、特应性皮炎等，并具有优越的药理作用、理化性质等。本发明涉及一种由以下式表示的化合物：其中每个符号如规范中定义的那样，或其盐。
• US9023858B2
  申请人：——

  公开号：US9023858B2

  公开（公告）日：2015-05-05
• Elucidation of the Mechanism of Pyrazinone Formation in Glycine Model Systems Using Labeled Sugars and Amino Acids
  作者：Anahita Keyhani、Varoujan A. Yaylayan

  DOI：10.1021/jf960067z

  日期：1996.1.1

  Model studies using D-[C-13]glucoses and a series of C-2, C-3, and C-4 dicarbonyl compounds with labeled [N-15/C-13]glycines have indicated that methyl-substituted pyrazines and pyrazinones formed in these model systems have a common intermediate. The labeling studies have also helped to identify a new chemical transformation of alpha-dicarbonyls, affected by the amino acid, that lead to the addition of the C-2 atom of the amino acid to the alpha-dicarbonyl compounds, instead of the amino group as in the case of the Strecker-type interaction between the two reactants. Thus, glyoxal and pyruvaldehyde can be transformed into pyruvaldehyde and 2,3-butanedione, respectively, by the amino acid. Two pathways of formation of pyrazinones were distinguished on the basis of the labeling experiments, one involving the reaction of 3 mol of glycine and the other the interaction of the dipeptide glycylglycine with an alpha-dicarbonyl compound.